1. Home
  2. ABTC vs ALLO Comparison

ABTC vs ALLO Comparison

Compare ABTC & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Bitcoin Corp.

ABTC

American Bitcoin Corp.

HOLD

Current Price

$4.30

Market Cap

386.0M

Sector

Technology

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$0.76

Market Cap

452.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABTC
ALLO
Founded
2024
2017
Country
United States
United States
Employees
59
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
386.0M
452.6M
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
ABTC
ALLO
Price
$4.30
$0.76
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
12
Target Price
★ $15.75
$9.00
AVG Volume (30 Days)
943.3K
★ 11.2M
Earning Date
11-04-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 66.67
34.09
EPS
★ N/A
N/A
Revenue
★ $185,164,000.00
N/A
Revenue This Year
$46.17
N/A
Revenue Next Year
$18.18
$72.02
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 801.52
N/A
52 Week Low
$4.27
$0.74
52 Week High
$374.25
$4.46

Technical Indicators

Market Signals
Indicator
ABTC
ALLO
Relative Strength Index (RSI) 27.23 21.26
Support Level N/A N/A
Resistance Level $9.16 $2.25
Average True Range (ATR) 0.54 0.10
MACD -0.14 -0.02
Stochastic Oscillator 0.14 0.42

Price Performance

Historical Comparison
ABTC
ALLO

About ABTC American Bitcoin Corp.

American Bitcoin Corp is a Bitcoin accumulation platform that integrates scaled Bitcoin mining operations with disciplined accumulation strategies. Its business is engaged in the operation of application-specific integrated circuit ("ASIC") miners for mining Bitcoin and the strategic accumulation of a Bitcoin reserve.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

Share on Social Networks: